Raman Singh Biography and Net Worth

Director of Liquidia

Mr. Singh is the Founder, Shareholder, Director and a Board Member of Juniper Biologics, a science-led healthcare company headquartered in Singapore that is researching, developing and commercializing innovative medications in the areas of Oncology, Rare and Orphan Diseases, and Gene Therapy. Prior to his current role, Mr. Singh was Chief Executive Officer of Mundipharma Pte Limited, which is part of a network of independent associated companies active in the fields of respiratory, oncology, pain and biosimilars. He has also served in various commercial roles for multi-national pharmaceutical companies including, vice president of commercial operations for emerging markets at GSK, regional leadership roles in Australia, New Zealand, and Korea for Abbott, as well as various sales, marketing and strategy positions at Bayer. Mr. Singh graduated with a Bachelors in Mechanical Engineering. He also holds Masters of Business Administration from Assumption University and Masters in International Management from Thunderbird School of International Management. He currently serves on the boards of Biofourmis Healthcare and Neuroglee Therapeutics.

What is Raman Singh's net worth?: The estimated net worth of Raman Singh is at least $1.06 million as of September 15th, 2025. Singh owns 31,255 shares of Liquidia stock worth more than $1,060,170 as of December 4th. This net worth estimate does not reflect any other assets that Singh may own. Learn More about Raman Singh's net worth.
How do I contact Raman Singh?: The corporate mailing address for Singh and other Liquidia executives is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. Liquidia can also be reached via phone at (919) 328-4400 and via email at [email protected]. Learn More on Raman Singh's contact information.
Has Raman Singh been buying or selling shares of Liquidia?: Raman Singh has not been actively trading shares of Liquidia during the last ninety days. Most recently, Raman Singh sold 45,524 shares of the business's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $25.81, for a transaction totalling $1,174,974.44. Following the completion of the sale, the director now directly owns 31,255 shares of the company's stock, valued at $806,691.55. Learn More on Raman Singh's trading history.
Who are Liquidia's active insiders?: Liquidia's insider roster includes Jason Adair (Chief Business Officer), Dana Boyle (CAO), Roger Jeffs (CEO), Michael Kaseta (CFO), Arthur Kirsch (Director), Sarah Krepp (Insider), Paul Manning (Director), Scott Moomaw (Chief Commercial Officer), Rajeev Saggar (Insider), Russell Schundler (General Counsel), and Raman Singh (Director). Learn More on Liquidia's active insiders.
Are insiders buying or selling shares of Liquidia?: In the last year, insiders at the sold shares 52 times. They sold a total of 1,155,124 shares worth more than $29,483,872.80. The most recent insider tranaction occured on December, 1st when General Counsel Russell Schundler sold 1,072 shares worth more than $34,507.68. Insiders at Liquidia own 26.5% of the company. Learn More about insider trades at Liquidia.
Information on this page was last updated on 12/1/2025.

Raman Singh Insider Trading History at Liquidia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/15/2025	Sell	45,524	$25.81	$1,174,974.44	31,255
9/3/2025	Sell	7,500	$29.42	$220,650.00	31,255

Raman Singh Buying and Selling Activity at Liquidia

Liquidia Company Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Today's Range

Now: $33.92

$33.00

$34.08

50 Day Range

MA: $26.04

$21.80

$33.92

2 Week Range

Now: $33.92

$10.37

$34.08

Volume

880,832 shs

Average Volume

1,935,568 shs

Market Capitalization

$2.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48